Clinical Trial Update: Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating 99mTc-MIP-1404 SPECT/CT imaging in men with biopsy-proven low-grade prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 99mTc-MIP-1404 (Technetium-99m MIP-1404)

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED